lebrikizumab Report issue

Biologics mAb Experimental
AACT ChEMBL DrugBank

Active Ingredient History

NOW
  • Now
Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

lebrikizumab | milr1444a | pro-301444 | pro-301444 rg-3637 | rg-3637 | tnx-650

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Asthma (Phase 3)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Eczema (Phase 3)

Healthy Volunteers (Phase 1)

Hodgkin Disease (Phase 1/Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Skin Diseases (Phase 3)

Skin Diseases, Genetic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 36
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue